Paul is an Associate in Fund III and brings over ten years of experience in sourcing, evaluating, and funding life sciences technologies and companies across multiple modalities and therapeutic areas. Paul’s responsibilities include conducting due diligence, participating in deal structuring and closure, and monitoring portfolio companies. Paul participated in the closure of key deals within Fund III, including Amolyt Pharma, enGene, Thryv Therapeutics, and Glycomine. He serves as a board observer for Find Therapeutics.

Before joining CTI, Paul served as a Licensing and Commercialization Associate specializing in Business Intelligence at the University Health Network (UHN), Canada’s top Research Commercialization Institute. While at UHN, Paul advised on licensing, partnering, and financing deals for UHN assets and spinout companies, including a $91M Series B financing to UHN spinout company Treadwell Therapeutics. Before UHN, Paul was a Scientist and Business Development Manager at adMare BioInnovations and Director of Scientific Affairs at Canada’s Stem Cell Network. Paul holds a Ph.D. in stem cell biology and functional genomics from the Institute of Medical Science at the University of Toronto and a BSc in Pharmacology from McMaster University.